Menée sur 211 patients atteints d'un carcinome hépatocellulaire de stade intermédiaire traité par chimio-embolisation transartérielle, cette étude évalue, du point de vue du contrôle local de la maladie et des taux de survie à à 1, 3 et 5 ans, l'efficacité d'une ablation par radiofréquences

Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma

Yin, Xin ; Zhang, Lan ; Wang, Yan-Hong ; Zhang, Bo-Heng ; Gan, Yu-Hong ; Ge, Ning-Lin ; Chen, Yi ; Li, Li-Xin ; Ren, Zheng-Gang

Background : This study was designed to evaluate the effectiveness of radiofrequency ablation in patients with intermediate (BCLC B) stage hepatocellular carcinoma who underwent transcatheter arterial chemoembolization. Methods : Included in this study were 211 patients with intermediate stage HCC who underwent initial transcatheter arterial chemoembolization and were potentially amendable for radiofrequency ablation (single tumor with diameter 5-8 cm, median 6.0 cm; 2-5 multiple nodules with [...]

Menée sur 394 patients atteints d'un cancer localisé de la prostate traité entre 2010 et 2012 (durée médiane de suivi : 47 mois), cette étude compare la toxicité d'une protonthérapie et d'une radiothérapie avec modulation d'intensité

A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer

Fang, Penny ; Mick, Rosemarie ; Deville, Curtiland ; Both, Stefan ; Bekelman, Justin E. ; Christodouleas, John P. ; Guzzo, Thomas J. ; Tochner, Zelig ; Hahn, Stephen M. ; Vapiwala, Neha

BACKGROUND : The authors assessed whether proton beam therapy (PBT) for prostate cancer (PCa) was associated with differing toxicity compared with intensity-modulated radiation therapy (IMRT) using case-matched analysis. METHODS : From 2010 to 2012, 394 patients who had localized PCa received 79.2 Gray (Gy) relative biologic effectiveness (RBE) delivered with either PBT (181 patients) or IMRT (213 patients). Patients were case-matched on risk group, age, and prior gastrointestinal (GI) and [...]

Menée à partir de données portant sur deux cohortes incluant au total 12 025 patientes atteintes d'un cancer invasif du sein traité par chirurgie conservatrice et radiothérapie externe entre 1980 et 2005, cette étude évalue, selon les critères de deux études ("TARGIT A " et "RIOP"), la proportion de patientes éligibles pour une radiothérapie intra-opératoire du sein, puis évalue la survie sans récidive locale à 5 ans de ces patientes

Eligibility criteria for intraoperative radiotherapy for breast cancer: study employing 12,025 patients treated in two cohorts

Zioueche-Mottet, Amira ; Houvenaeghel, Gilles ; Classe, Jean ; Garbay, Jean ; Giard, Sylvia ; Charitansky, Helene ; Cohen, Monique ; Belichard, Catherine ; Faure, Christelle ; Chereau Ewald, Elisabeth ; Hudry, Delphine ; Azuar, Pierre ; Villet, Richard ; Gimbergues, Pierre ; Tunon de Lara, Christine ; Tallet, Agnes ; Bannier, Marie ; Minsat, Mathieu ; Lambaudie, Eric ; Resbeut, Michel

Background : We wished to estimate the proportion of patients with breast cancer eligible for an exclusive targeted intraoperative radiotherapy (TARGIT) and to evaluate their survival without local recurrence. Methods : We undertook a retrospective study examining two cohorts. The first cohort was multicentric (G3S) and contained 7580 patients. The second cohort was monocentric (cohort 2) comprising 4445 patients. All patients underwent conservative surgery followed by external radiotherapy for [...]

Menée à partir des données 1988-2007 de 17 registres américains des cancers portant sur 61 523 patients atteints d'un cancer de la thyroïde, cette étude évalue la mortalité spécifique en fonction des caractéristiques de la maladie (sous-type histologique, taille de la tumeur, ...) et analyse la pertinence d'une intervention chirurgicale pour les patients présentant un cancer papillaire de la thyroïde dont la tumeur présente une taille inférieure ou égale à 2 cm

Should small papillary thyroid cancer be observed? A population-based study

Nilubol, Naris ; Kebebew, Electron

BACKGROUND : Some centers have advocated selecting patients with small papillary thyroid cancer (PTC) to undergo active surveillance without surgical treatment. The objectives of the current study were to analyze thyroid cancer (TC)-related mortality in a population-based cohort and to determine the impact of small PTCs (defined as tumors ≤2 cm in greatest dimension) on TC-related mortality. METHODS : Data on patients with TC of follicular cell origin from the National Cancer Institute's [...]

Menée à l'aide de modèles murins, cette étude évalue l'activité antitumorale d'un traitement combinant une thérapie cellulaire par transfert adoptif de lymphocytes T et un anticorps bispécifique anti-EGFR et anti-EpCAM

Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer

Kobold, Sebastian ; Steffen, Julius ; Chaloupka, Michael ; Grassmann, Simon ; Henkel, Jonas ; Castoldi, Raffaella ; Zeng, Yi ; Chmielewski, Markus ; Schmollinger, Jan C. ; Schnurr, Max ; Rothenfußer, Simon ; Schendel, Dolores J. ; Abken, Hinrich ; Sustmann, Claudio ; Niederfellner, Gerhard ; Klein, Christian ; Bourquin, Carole ; Endres, Stefan

Background: One bottleneck for adoptive T cell therapy (ACT) is recruitment of T cells into tumors. We hypothesized that combining tumor-specific T cells, modified with a marker antigen and a bispecific antibody (BiAb) that selectively recognizes transduced T cells and tumor cells would improve T cell recruitment to tumors and enhance therapeutic efficacy. Methods: SV40 T antigen–specific T cells from T cell receptor (TCR)-I–transgenic mice were transduced with a truncated human epidermal [...]

Cet article analyse les perspectives offertes par l'immunothérapie pour induire la dormance permanente des cellules tumorales ou éliminer les cellules tumorales dormantes

The Inherent Premise of Immunotherapy for Cancer Dormancy

Manjili, Masoud H.

Clinical cancer dormancy is evident from the detection of circulating tumor cells in the blood and tissue-residing disseminated tumor cells in the bone marrow of cancer survivors who have been clinically disease free. Emerging evidence from clinical and preclinical studies suggests that tumor dormancy is a critical step in the development of both primary cancer and advanced-stage disease. In this review, it is shown that (i) naturally occurring tumor dormancy precedes occurrence of primary [...]

Menée à l'aide de modèle murins, cette étude suggère l'intérêt d'une stratégie basée sur l'inhibition du complexe DOT1L/AF10 pour le traitement des leucémies myéloïdes aiguës présentant une sous-expression du gène HOXA

AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes

Deshpande, Aniruddha J ; Deshpande, Anagha ; Sinha, Amit U ; Chen, Liying ; Chang, Jenny ; Cihan, Ali ; Fazio, Maurizio ; Chen, Chun-wei ; Zhu, Nan ; Koche, Richard ; Dzhekieva, Liuda ; Ibáñez, Gloria ; Dias, Stuart ; Banka, Deepti ; Krivtsov, Andrei ; Luo, Minkui ; Roeder, Robert G ; Bradner, James E ; Bernt, Kathrin M ; Armstrong, Scott A

Homeotic (HOX) genes are dysregulated in multiple malignancies, including several AML subtypes. We demonstrate that H3K79 dimethylation (H3K79me2) is converted to monomethylation (H3K79me1) at HOX loci as hematopoietic cells mature, thus coinciding with a decrease in HOX gene expression. We show that H3K79 methyltransferase activity as well as H3K79me1-to-H3K79me2 conversion is regulated by the DOT1L cofactor AF10. AF10 inactivation reverses leukemia-associated epigenetic profiles, precludes [...]

Menée in vitro et in vivo, cette étude met en évidence des mécanismes par lesquels un analogue synthétique de l’amyline induit une régression de lymphomes n’exprimant pas le gène p53

IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo

Venkatanarayan, Avinashnarayan ; Raulji, Payal ; Norton, William ; Chakravarti, Deepavali ; Coarfa, Cristian ; Su, Xiaohua ; Sandur, Santosh K. ; Ramirez, Marc S. ; Lee, Jaehuk ; Kingsley, Charles V. ; Sananikone, Eliot F. ; Rajapakshe, Kimal ; Naff, Katherine ; Parker-Thornburg, Jan ; Bankson, James A. ; Tsai, Kenneth Y. ; Gunaratne, Preethi H. ; Flores, Elsa R.

TP53 is commonly altered in human cancer, and Tp53 reactivation suppresses tumours in vivo in mice (TP53 and Tp53 are also known as p53). This strategy has proven difficult to implement therapeutically, and here we examine an alternative strategy by manipulating the p53 family members, Tp63 and Tp73 (also known as p63 and p73, respectively). The acidic transactivation-domain-bearing (TA) isoforms of p63 and p73 structurally and functionally resemble p53, whereas the

Menée sur des lignées cellulaires et à l'aide de xénogreffes de cancer du sein ER+, cette étude met en évidence le rôle joué par l'expression du gène MACROD2 dans la résistance au tamoxifène

MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers

Mohseni, Morassa ; Cidado, Justin ; Croessmann, Sarah ; Cravero, Karen ; Cimino-Mathews, Ashley ; Wong, Hong Yuen ; Scharpf, Rob ; Zabransky, Daniel J. ; Abukhdeir, Abde M. ; Garay, Joseph P. ; Wang, Grace M. ; Beaver, Julia A. ; Cochran, Rory L. ; Blair, Brian G. ; Rosen, D. Marc ; Erlanger, Bracha ; Argani, Pedram ; Hurley, Paula J. ; Lauring, Josh ; Park, Ben Ho

Tamoxifen is effective for treating estrogen receptor-alpha (ER) positive breast cancers. However, few molecular mediators of tamoxifen resistance have been elucidated. Here we describe a previously unidentified gene, MACROD2 that confers tamoxifen resistance and estrogen independent growth. We found MACROD2 is amplified and overexpressed in metastatic tamoxifen-resistant tumors. Transgene overexpression of MACROD2 in breast cancer cell lines results in tamoxifen resistance, whereas [...]

Menée in vitro et in vivo, cette étude met en évidence des mécanismes par lesquels, en bloquant l'angiogenèse et la lymphangiogenèse, un peptide biomimétique dérivé du collagène de type IV inhibe la croissance tumorale et le processus métastatique d'un cancer du sein

Inhibition of breast cancer growth and metastasis by a biomimetic peptide

Lee, Esak ; Lee, Seung Jae ; Koskimaki, Jacob E. ; Han, Zheyi ; Pandey, Niranjan B. ; Popel, Aleksander S.

Metastasis is the main cause of mortality in cancer patients. Though there are many anti-cancer drugs targeting primary tumor growth, anti-metastatic agents are rarely developed. Angiogenesis and lymphangiogenesis are crucial for cancer progression, particularly, lymphangiogenesis is pivotal for metastasis in breast cancer. Here we report that a novel collagen IV derived biomimetic peptide inhibits breast cancer growth and metastasis by blocking angiogenesis and lymphangiogenesis. The peptide [...]

Menée sur des lignées cellulaires de cancer du sein, cette étude met en évidence plusieurs mécanismes de résistance au cabazitaxel

Mechanisms of Resistance to Cabazitaxel

Duran, George E ; Wang, Yan C. ; Francisco, E. Brian ; Rose, John C. ; Martinez, Francisco J. ; Coller, John ; Brassard, Diana ; Vrignaud, Patricia ; Sikic, Branimir I.

We studied mechanisms of resistance to the novel taxane cabazitaxel in established cellular models of taxane resistance. We also developed cabazitaxel-resistant variants from MCF-7 breast cancer cells by stepwise selection in drug alone (MCF-7/CTAX) or drug plus the transport inhibitor PSC-833 (MCF-7/CTAX-P). Among multidrug resistant (MDR) variants, cabazitaxel was relatively less cross-resistant than paclitaxel and docetaxel (15 vs. 200-fold in MES-SA/Dx5 and 9 vs. 60-fold in MCF-7/TxT50, [...]

Cet article passe en revue les perspectives offertes par le développement de nouvelles thérapies ciblées pour les patients atteints d'un carcinome invasif de la vessie

Emerging Therapeutic Targets in Bladder Cancer

Carneiro, Benedito A. ; Meeks, Joshua J. ; Kuzel, Timothy M. ; Scaranti, Mariana ; Abdulkadir, Sarki A. ; Giles, Francis J.

Treatment of muscle invasive urothelial bladder carcinoma (BCa) remains a major challenge. Comprehensive genomic profiling of tumors and identification of driver mutations may reveal new therapeutic targets. This manuscript discusses relevant molecular drivers of the malignant phenotype and agents with therapeutic potential in BCa. Small molecule pan-FGFR inhibitors have shown encouraging efficacy and safety results especially among patients with activating FGFR mutations or translocations. [...]

Mené sur 248 patients atteints d'un adénocarcinome gastrique métastatique ou localement récidivant, cet essai de phase II compare l'efficacité, du point de vue de la survie sans progression, et la toxicité de trois combinaisons de chimiothérapie (docétaxel-oxaliplatine, docétaxel-oxaliplatine-5FU, docétaxel-oxaliplatine-capécitabine)

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

Van Cutsem, E. ; Boni, C. ; Tabernero, J. ; Massuti, B. ; Middleton, G. ; Dane, F. ; Reichardt, P. ; Pimentel, F.L. ; Cohn, A. ; Follana, P. ; Clemens, M. ; Zaniboni, A. ; Moiseyenko, V. ; Harrison, M. ; Richards, D.A. ; Prenen, H. ; Pernot, S. ; Ecstein-Fraisse, E. ; Hitier, S. ; Rougier, P.

Background : Docetaxel/cisplatin/infusional 5-fluorouracil (DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer. This phase II study evaluated docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/5-fluorouracil (TEF) and docetaxel/oxaliplatin/capecitabine (TEX) in patients with advanced gastric cancer. Patients and methods : Patients with metastatic or locally recurrent gastric adenocarcinoma (including carcinoma of the gastroesophageal junction) were randomized [...]

Mené sur 418 patients atteints d'un mélanome métastatique sans mutation du gène BRAF, cet essai randomisé de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité du nivolumab par rapport à la dacarbazine

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, Caroline ; Long, Georgina V. ; Brady, Benjamin ; Dutriaux, Caroline ; Maio, Michele ; Mortier, Laurent ; Hassel, Jessica C. ; Rutkowski, Piotr ; McNeil, Catriona ; Kalinka-Warzocha, Ewa ; Savage, Kerry J. ; Hernberg, Micaela M. ; Lebbé, Celeste ; Charles, Julie ; Mihalcioiu, Catalin ; Chiarion-Sileni, Vanna ; Mauch, Cornelia ; Cognetti, Francesco ; Arance, Ana ; Schmidt, Henrik ; Schadendorf, Dirk ; Gogas, Helen ; Lundgren-Eriksson, Lotta ; Horak, Christine ; Sharkey, Brian ; Waxman, Ian M. ; Atkinson, Victoria ; Ascierto, Paolo A.

BACKGROUND : Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study. METHODS : We randomly assigned 418 previously untreated patients who had metastatic melanoma without a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight [...]

Mené sur 704 patients atteints d'un mélanome métastatique présentant la mutation V600E du gène BRAF, cet essai randomisé de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité d'un traitement combinant dabrafenib et tramatinib par rapport au vemurafenib seul

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Robert, Caroline ; Karaszewska, Boguslawa ; Schachter, Jacob ; Rutkowski, Piotr ; Mackiewicz, Andrzej ; Stroiakovski, Daniil ; Lichinitser, Michael ; Dummer, Reinhard ; Grange, Florent ; Mortier, Laurent ; Chiarion-Sileni, Vanna ; Drucis, Kamil ; Krajsova, Ivana ; Hauschild, Axel ; Lorigan, Paul ; Wolter, Pascal ; Long, Georgina V. ; Flaherty, Keith ; Nathan, Paul ; Ribas, Antoni ; Martin, Anne-Marie ; Sun, Peng ; Crist, Wendy ; Legos, Jeff ; Rubin, Stephen D. ; Little, Shonda M. ; Schadendorf, Dirk

BACKGROUND : The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients. METHODS : In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a [...]

Cet article passe en revue les traitements actuellement disponibles pour les patients atteints d'un myélome multiple récidivant et/ou réfractaire

Current treatment landscape for relapsed and/or refractory multiple myeloma

Dimopoulos, Meletios A. ; Richardson, Paul G. ; Moreau, Philippe ; Anderson, Kenneth C.

Recent developments in the treatment of multiple myeloma have led to improvements in response rates and to increased survival; however, relapse is inevitable in almost all patients. Recurrence of myeloma is typically more aggressive with each relapse, leading to the development of treatment-refractory disease, which is associated with a shorter survival. Several phase II and III trials have demonstrated the efficacy of recently approved agents in the setting of relapsed and/or refractory [...]

Mené sur 2 716 patientes atteintes d'un cancer du sein de stade précoce à haut risque, cet essai de phase III compare l'efficacité, du point de vue de la survie sans maladie, de quatre schémas d'administration d'un traitement adjuvant à base d'anthracyclines et de taxanes (durée médiane de suivi : 6 ans)

SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer

Budd, George T. ; Barlow, William E. ; Moore, Halle C.F. ; Hobday, Timothy J. ; Stewart, James A. ; Isaacs, Claudine ; Salim, Muhammad ; Cho, Jonathan K. ; Rinn, Kristine J. ; Albain, Kathy S. ; Chew, Helen K. ; Burton, Gary V. ; Moore, Timothy D. ; Srkalovic, Gordan ; McGregor, Bradley A. ; Flaherty, Lawrence E. ; Livingston, Robert B. ; Lew, Danika L. ; Gralow, Julie R. ; Hortobagyi, Gabriel N.

Purpose : To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. Patients and Methods : A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophosphamide was superior to six cycles of doxorubicin-cyclophosphamide once every 2 weeks and (2) that paclitaxel once per week was superior to six cycles of paclitaxel once every 2 weeks in patients with [...]

Cet article fait le point sur les avancées en matière de traitements adjuvants et néoadjuvants des patients atteints d'un cancer de l'estomac

Adjuvant and/or neoadjuvant therapy for gastric cancer ? A perspective review

Schirren, Rebekka ; Reim, Daniel ; Novotny, Alexander R.

Surgery is still the only curative therapy for locoregional gastric cancer. Hereby it is important to achieve negative margins (R0 resection) and to perform an adequate lymph-node dissection (D2 lymphadenectomy). Unfortunately most cases of gastric cancer are diagnosed in a locally advanced tumor stage. The poor prognosis of patients with these tumors is due to the frequent recurrences after primary resection in curative intent. This observation led to the development of (neo)adjuvant treatment [...]

Menée in vitro et à l'aide d'un modèle murin, cette étude évalue l'efficacité de l'immunophotothérapie en proche infrarouge pour traiter un cancer de l'ovaire avec dissémination péritonéale

Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer

Sato, Kazuhide ; Hanaoka, Hirofumi ; Watanabe, Rira ; Nakajima, Takahito ; Choyke, Peter L ; Kobayashi, Hisataka

Near infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that combines the specificity of intravenously injected antibodies for targeting tumors with the toxicity induced by photosensitizers after exposure to near infrared (NIR) light. Herein, we evaluate the efficacy of NIR-PIT in a mouse model of disseminated peritoneal ovarian cancer. In vitro and in vivo experiments were conducted with a HER2-expressing, luciferase expressing, ovarian cancer cell line (SKOV-luc). An [...]

Menée à partir de données portant sur 1 842 patients atteints d'un cancer du poumon non à petites cellules de stade III traité entre 2001 et 2010, cette étude compare l'efficacité, du point de vue de la survie globale, et les effets secondaires d'un traitement par étoposide-cisplatine et d'un traitement par carboplatine-paclitaxel en combinaison avec une radiothérapie concomitante

Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non–Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data

Santana-Davila, Rafael ; Devisetty, Kiran ; Szabo, Aniko ; Sparapani, Rodney ; Arce-Lara, Carlos ; Gore, Elizabeth M. ; Moran, Amy ; Williams, Christina D. ; Kelley, Michael J. ; Whittle, Jeffrey

Purpose : The optimal chemotherapy regimen to use with radiotherapy in stage III non–small-cell lung cancer is unknown. Here, we compare the outcome of patents treated within the Veterans Health Administration with either etoposide-cisplatin (EP) or carboplatin-paclitaxel (CP). Methods : We identified patients treated with EP and CP with concurrent radiotherapy from 2001 to 2010. Survival rates were compared using Cox proportional hazards regression models with adjustments for confounding [...]

Menée à partir de données portant sur 1 155 patients atteints d'un cancer colorectal avec métastases synchrones non résécables et inclus dans quatre essais évaluant une chimiothérapie de première ligne, cette étude française évalue l'intérêt de réséquer la tumeur primitive pour améliorer la survie globale des patients

Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials

Faron, Matthieu ; Pignon, Jean-Pierre ; Malka, David ; Bourredjem, Abderrahmane ; Douillard, Jean-Yves ; Adenis, Antoine ; Elias, Dominique ; Bouche, Olivier ; Ducreux, Michel

Objective : To evaluate the impact on survival of primary tumour resection in patients with unresectable synchronous metastases from colorectal cancer (CRC). Summary background data : Primary tumour resection in this setting remains controversial. Patients and methods : We retrieved individual data of 1155 patients with metastatic CRC included in four first-line chemotherapy trials: Fédération Francophone de Cancérologie Digestive (FFCD)-9601, FFCD-2000-05, Actions Concertées dans les cancers [...]

Cet article fait le point sur l'évolution des stratégies thérapeutiques pour traiter des ganglions lymphatiques régionaux chez les patientes atteintes d'un cancer du sein, puis analyse les controverses concernant le rôle d'une radiothérapie des ganglions régionaux dans le cadre d'un traitement personnalisé

The Evolution of Regional Nodal Irradiation in Breast Cancer

Haffty, Bruce G. ; Mahmoud, Omar

Breast cancer regional node management has witnessed many changes over the last decade. Advances in surgical techniques establishing sentinel lymph node biopsy as an alternative to axillary dissection, use of microarray technology for subtyping breast cancer to guide systemic therapy selection, and the expansion of the systemic therapy armamentarium including targeted agents have contributed to changing our strategy from one size fits all to a more tailored approach. There have also been recent [...]

Cet article passe en revue les travaux qui, depuis la découverte de l'oncogène Met en 1984, ont ouvert la voie à quelque 240 essais cliniques évaluant divers inhibiteurs de Met

Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside

Furlan, Alessandro ; Kherrouche, Zoulika ; Montagne, Rémi ; Copin, Marie-Christine ; Tulasne, David

Met receptor tyrosine kinase was discovered in 1984 as an oncogene. Thirty years later, Met and its ligand hepatocyte growth factor/scatter factor are promising targets for the novel therapies developed to fight against cancers, with more than 240 clinical trials currently conducted. In this review, we offer to trace and highlight the most recent findings of the exemplary track record of research on Met receptor, which allowed moving this biomarker from bench to bedside. Indeed, three decades [...]

Cet article fait le point sur les techniques permettant d'identifier les patients présentant une hypersensibilité aux rayonnements ionisants

Late side-effects after curative intent radiotherapy: identification of hypersensitive patients for personalized strategy

Bourgier, Céline ; Lacombe, Jérôme ; Solassol, Jérôme ; Mange, Alain ; Pèlegrin, André ; Ozsahin, Mahmut ; Azria, David

Radiation therapy undeniably enhances local control and thus improves overall survival in cancer patients. However, some long-term cancer survivors (less than 10%) develop severe late radio-induced toxicities altering their quality of life. Therefore, there is a need to identify patients who are sensitive to those toxicities and who could benefit from adapted care. In this review, we address all available techniques aiming to detect patients’ hyper-radiosensitivity and present the scientific [...]

Cet article passe en revue les travaux récents sur l'intérêt de l'acide tout-trans rétinoïque pour le traitement des types de leucémies myéloïdes aiguës autres que la leucémie promyélocytaire aiguë

Unlocking the potential of retinoic acid in anticancer therapy

Schenk, T. ; Stengel, S. ; Zelent, A.

All-trans-retinoic acid (ATRA) is a physiologically active metabolite of vitamin A. Its antitumour activities have been extensively studied in a variety of model systems and clinical trials; however, to date the only malignancy responsive to ATRA treatment is acute promyelocytic leukaemia (APL) where it induces complete remission in the majority of cases when administered in combination with light chemotherapy and/or arsenic trioxide. After decades of studies, the efficacy of ATRA to treat [...]

Cet article passe en revue les travaux récents sur la prise en charge des patients atteints d'un myélome multiple indolent à haut risque

Dilemmas in Treating Smoldering Multiple Myeloma

Ahn, Inhye E. ; Mailankody, Sham ; Korde, Neha ; Landgren, Ola

Novel therapies hold promise for high-risk smoldering multiple myeloma (SMM). Recent studies suggest that modern combination approaches can be options for high-risk SMM to obtain deep molecular responses with favorable toxicity profiles. Although pioneering treatment trials based on small numbers of patients suggest progression-free and overall survival benefits, application of the data to real-life practice remains to be validated. Therapeutic modulation of disease tempo, disease burden, [...]

Cet article passe en revue les travaux récents sur la prise en charge des patients atteints d'un cancer du testicule

Testicular Cancer — Discoveries and Updates

Hanna, Nasser H. ; Einhorn, Lawrence H.

The treatment of testicular cancer is a success story in oncology. With available methods, 95% of men with this condition can be cured. Emphasis is shifting toward maintaining high cure rates and reducing or effectively managing late effects of treatment.